AMTRIX-D

Phase 2Biologic

TTBF Genie Tissulaire

AMTRIX-D is one of 7 biologic programs targeting Surgical. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SurgicalRecruiting

SurgicalPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Surgical

#DrugCompanyPhaseTrials

Naropin

FFresenius Kabi USA, LLC

Phase 2

1 2

Xyrem

Jazz Pharmaceuticals

Preclinical

1 3

TLC590

TTLC Biopharmaceuticals, Inc.

Phase 2

1 4

AMTRIX-D

TTBF Genie Tissulaire

Phase 2

1 5

Platelet Rich Fibrin

GGovernment Dental College and Research Institute, Bangalore

Preclinical

1 6

Sodium Hypochlorite Gel Application

UUniversity of Messina

Preclinical

1 7

TISSEEL

UUniversity Hospital, Ghent

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Surgical1 trial

Surgical Release of Hand Tendons with Wrapping of the Released Tendon Using an Amniotic Membrane

Recruiting·TTBF Genie Tissulaire·Phase 2·NCT06723782·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMTRIX-D. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMTRIX-D compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMTRIX-D. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TBF Genie Tissulaire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TTBF Genie Tissulaire

AMTRIX-D

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Surgical1 trial

References

Drug Info

Quick Facts

Related News